MRTX News and Press, Mirati Therapeutics Inc. From 09/27/23

Mirati To Present Updated Clinical Data at ESMO Congress 2023 PR Newswire Late-Breaking KRYSTAL-7 data demonstrates compelling efficacy and safety of adagrasib in combination with pembrolizumab in 1L NSCLC Data follows recent inclusion of the adagrasib in co...

2023-09-19 12:25:41 ET FN Media Group Presents USA News Group News Commentary Vancouver, BC – September 19, 2023 – USA News Group –  A new cancer-focused venture capital firm is making headlines, having debuted with $200 million in funding f...

Mirati Presents Two-Year Follow-Up Data from KRYSTAL-1 Study Demonstrating Durable Response and Long-Term Overall Survival at 2023 World Conference on Lung Cancer PR Newswire SAN DIEGO , Sept. 9, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. ® (NASD...

Mirati Therapeutics to Participate at the Morgan Stanley 21st Annual Global Healthcare Conference PR Newswire SAN DIEGO , Aug. 29, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. ® (NASDAQ: MRTX), a commercial stage biotechnology company, will partici...

2023-08-28 07:54:44 ET Summary Results from the phase 1/2 study using MRTX1133 for the treatment of patients with KRAS G12D mutated tumors are expected by the 1st half of 2024. Completion of supplemental New Drug Application of adagrasib for the treatment of patients with colorect...

2023-08-23 16:37:15 ET More on Mirati Therapeutics Mirati Therapeutics, Inc. 2023 Q2 - Results - Earnings Call Presentation Mirati Therapeutics, Inc. ( MRTX ) Q2 2023 Earnings Call Transcript Mirati Therapeutics: EU Rejection Clouds Krazati's Prospects Ci...

Mirati Therapeutics Announces Departure of Chief Financial Officer Laurie Stelzer PR Newswire SAN DIEGO , Aug. 23, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. ® (NASDAQ: MRTX), a commercial stage biotechnology company, today announced that Lauri...

Mirati To Present Pooled Clinical Data from Adagrasib's KRYSTAL-1 Study Demonstrating Overall Survival Results at Two-Years of Follow-Up at 2023 World Conference on Lung Cancer PR Newswire SAN DIEGO , Aug. 21, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. ...

2023-08-19 07:40:00 ET Most people have either had cancer themselves or know someone who has. According to the American Cancer Society, 1 in 3 people in the U.S. will be diagnosed with one of the numerous forms of cancer. Deciphera Pharmaceuticals (NASDAQ: DCPH) , Mirati Thera...

Mirati Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares PR Newswire SAN DIEGO , Aug. 11, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. (Nasdaq: MRTX), a commercial stage biotechnology c...